Peri-urethral Bulk Agent Injection of Bulkamid®
Launched by HOSPICES CIVILS DE LYON · Feb 14, 2023
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- * Inclusion Criteria :
- • women over 18
- • patients who received a first peri-urethral injection of Bulkamid® in the context of urinary incontinence
- • intervention between September 2020 and November 2022
- • person having expressed his non-opposition
- * Exclusion Criteria :
- • inability to understand the information given
- • person deprived of liberty
- • person under guardianship
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bron, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials